News

A former employee of Roche lodged a complaint against the company citing an article published in the Financial Times. The article alleged that Roche had sold large quantities

On the basis of the submitted data, the label allows the use of Erbitux plus irinotecan in second- and further lines of metastatic colorectal cancer. Erbitux was approved

Bravo is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for

According to the company, the Merlin@home transmitter’s wireless technology gives patients the additional comfort of having devices automatically checked. Since the transmitter initiates the scheduled follow-up and uses

Pursuant to the closing of this financing round, Frazier’s general partner, Patrick Heron, has joined the Collegium board of directors. Previous investors Boston Millennia Partners and Westfield Capital

The company is following advice provided by the drug safety monitoring board and the steering committee, which have been continuously monitoring the trial’s progress. On the basis of

The investors have agreed to purchase the shares at a purchase price of $17.85 per share resulting in gross proceeds of approximately $25.9 million to Pharmasset, before deducting

The family of six complementary patents covers methods of genetic analysis used to detect markers for multifactorial traits. According to the company, these methods range from identification of

The LabChip GX represents a low price entry system targeted at genomics applications, while the GXII combines both genomics and protein research applications. The LabChip GX series of